G/MA/QR/N/EU/5/Add.2  
 
18 March  2021 
(21-2272) Page: 1/4 
Committee on Market Access  Original: English  
 
  
NOTIFICATION PURSUANT TO THE DECISION ON NOTIFICATION  PROCEDURE S 
FOR QUANTITATIVE RESTRICTIONS (G/L/59/REV.1)  
EUROPEAN UNION 
Addendum  
The following communication, dated 16 March  2021, is being circulated at the request of the 
delegation of the European Union . 
 
A. Notifying Member : European Union  
B. Date of notification : 16 March  2021 
C. First time notification:  
 Yes 
 No, last notification was made in (doc. symbol ): G/MA/QR/N/EU/ 5 and 
G/MA/QR/N/EU/5/Add.1  
D. Type of notification:  
 1. Complet e (i.e. notification of all quantitative restrictions in force ) 
 2. Changes to a notification previously made in (doc symbol)  which are of the following 
nature : 
  2.1 Introduction of new restrictio ns, as listed in Section 1. 
  2.2 Elimination of restrictions, as described in G below . 
  2.3 Modification of a prev iously notified restriction, as described in Section 1. 
 3. Reverse notification of restrictions maintained by (Member ):  
E. The notification provides information for the follo wing biennial period 
(e.g.  2012 -2014): 2020-2022 and relates to restrictions in fo rce as of 30.01.2021  
F. This notification contains information* relating to:  
 Section  1: List of quantitative restrictions that are currently in force . 
 Section  2: Cross -reference to other WTO notifications with information on quantitative 
restrictions that are currently in force and additional information . 
 
* In English  only. G/MA/QR/N/EU/5/Add.2  
 
- 2 - 
 
  G. Comments of a general nature, including a description of the elimination of 
restrictions notified under D.2.2 and the date they ceased to be in force.   
 The EU is notifying the extension of  the export authorisation requirement for Covid -19 
vaccines, applicable to exports of vaccines pr oduced by companies with which the EU has 
Advance Purchase Agreements (notified in G/MA/QR/N/EU/5/Add.1), until 30 June 2021. 
Based on the principle of international solidarity, exports to more than 100 countries 
continue to be exempted from the measure, s uch as, in particular, exports related to 
COVAX, in the context of a humanitarian emergency response as well as to EFTA, the 
Western  Balkans and the EU neighbourhood . 
  
  G/MA/QR/N/EU/5/Add.2  
 
- 3 - Section  1: List of quantitative restrictions that are currently in force  
 
 
QR 
No.  General 
description of 
the restriction  Type of 
restriction  Tariff line 
code  (s) 
affected, based 
on HS (2017)  Detailed Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. Other 
Internatio nal 
Commitments  National legal basis and 
entry into force  Administration, 
modification of previously 
notified measures, and 
other comments  
1 2 3 4 5 6 7 
1 Export 
authorisation for 
COVID -19 
vaccines  
 NAL-X ex 3002 20  
ex 2933 99  
ex 2934 99  
ex 3002 90  
ex 3504 00  Vaccines against SARS -
related coronaviruses 
(SARS -CoV species), 
irrespective of their 
packaging, and active 
substances including 
master and working cell 
banks used for the 
manufacture of such 
vaccines  Protection of human life or 
health, inter alia  
 Commission Implementing 
Regulation (EU) 2021/442 
of 12 March 2021 making 
the exportation of certain 
products subject to the 
production of an export 
authorisation;  
Official Journal L 85, 
12.03.2021  
 
https://eur -
lex.europa.eu/legal -
content/EN/TXT/PDF/?uri=C
ELEX:32021R0442&from=E
N 
 
 
Application period: from 
13.03 .2021 until 30.06.2021  Administration: Competent 
authorities in EU Member 
States  
 
Authorisations are granted to 
the extent that the volume of 
exports is such that it does not 
pose a threat to the execution 
of Advance Purchase 
Agreements that the European 
Union has concluded with  
vaccine manufacturers.  
 
Exemptions include  
(see Article 1.9 of the 
regulation):  
 
- exports in the context of 
humanitarian aid;  
 
- exports to low and middle 
income countries in the 
COVAX Advance Market 
Commitment (AMC) list 
(https://www.gavi.org/news/
media -room/92 -low-middle -
income -economies -eligible -
access -covid-19-vaccines -
gavi-covax -amc);  
  G/MA/QR/N/EU/5/Add.2  
 
- 4 - QR 
No.  General 
description of 
the restriction  Type of 
restriction  Tariff line 
code  (s) 
affected, based 
on HS (2017)  Detailed Product 
Description  WTO Justification  
and Ground for 
Restriction, e.g. Other 
Internatio nal 
Commitments  National legal basis and 
entry into force  Administration, 
modification of previously 
notified measures, and 
other comments  
1 2 3 4 5 6 7 
       exports of goods purchased 
and/or delivered through 
COVAX, UNICEF and PAHO 
with destination to any other 
COVAX participating country;  
 
- Albania, Algeria, Andorra, 
Armenia, Azerbaijan, Belarus, 
Bosnia and Herzegovina, 
Egypt, Faeroe Islands, 
Georgia, Holy See, Iceland, 
Israel, Jordan, Kosovo1, 
Lebanon, Libya, Liechtenstein, 
Moldova, Montenegro, 
Morocco, Norway, North 
Macedonia, Palestine2, San 
Marino, Serbia, Switzerland, 
Syria, Tunisia, Ukraine;  
 
- EU overseas countries and 
territories  
 
 
__________  
 
1 This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence . 
2 This designation shall not be construed as recognition of a State of Palestine and is without prejudice to the individual pos itions of the EU Member States on this 
issue.